Skip to content

Released Nov 7, 2016, after the close

10-Q filed Nov 7, 2016, 38 days after period end · 0001564590-16-027939

Q3 2016 · 10-Q
Revenue$1.03M±0.0% vs Q3 2015−0.1% vs Q2 2016
Net Income-$8.74MN/M vs Q3 2015N/M vs Q2 2016
EPS Diluted-$0.27N/M vs Q3 2015N/M vs Q2 2016
Operating Income-$8,389,000N/M
Operating Cash Flowderived-$7,516,000N/M
Free Cash Flowderived-$7,549,000N/M
Margins · derived
Operating margin-817.6%−200.9 pt vs Q3 2015
Net margin-851.6%−180.4 pt vs Q3 2015

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2016Q3 2015Q3 2014Q3 2013
Revenue$1.03M$1.03M—$209.00K
Net Income-$8.74M-$6.89M-$6.60M-$6.07M
EPS Diluted-$0.27-$0.24-$0.32-$4.81

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR